X-Therma logo


X-Therma Announces Oversubscribed Series A Financing

RICHMOND, Calif. — December 22, 2021 — 6:00 AM PT —  X-Therma Inc., a biotechnology company developing breakthrough technology for regenerative medicine and organ preservation – has closed an oversubscribed $13M Series A funding round. The financing is led by LOREA AG, an entrepreneur-operated investment firm, with participation from Zen11 Holdings, Graphene Ventures, VU Venture Partners, 2b AHEAD Ventures, Methuselah Foundation, Catalytic Impact Foundation, along with notable return angel investors.

X-Therma’s technology, a nontoxic biopreservation platform enabled by biomimetic peptoid, is transforming global accessibility to organ transplantation, as well as enabling “off-the-shelf” cell and gene therapy products and engineered tissues by providing safe & effective chemically defined cryopreservation that is DMSO-, serum-, and protein-free.

More and Better Organ Transplants

“We’re excited about the transformative impact of X-Therma’s technology and potential to better meet society’s demands of safely and successfully transplanting organs across the globe,” says Dr. Christoph Swarovski, owner and founder of LOREA AG. “Our conviction in this technology was inspired by the world’s dire need of a better solution for organ transport and we are fortunate to help X-Therma bring its vision to fruition.” X-Therma has made a quantum leap in demonstrating a significant extension of organ shelf-life from a few hours to a few days in collaboration with world-leading surgeon, Dr. Gerald Brandacher at Johns Hopkins University.

Less than 10% of the worldwide demand for transplantable organs is being met. Despite many improvements in surgical techniques and immunosuppression, innovations to extend the time window for safe and reliable organ preservation have, until now, fallen short. X-Therma’s turn-key solution XT-ViVo® and TimeSeal® in organ preservation removes this time constraint bottleneck without changing the peri-transplant workflow.

“Most organs are transported in a cooler filled with ice at 4°C. This provides very limited time to deliver organs to patients before they perish or to provide accurate matching,” says Dr. Mark Kline, CTO & Co-founder of X-Therma. “Our chemistry encodes specific protein-like functions into a synthetic molecule to shape ice crystals and prevent further growth into a detrimental size. This fundamentally enables us to safely store organs at sub-zero temperature, which improves transplantation from both organ accessibility and quality perspectives with extended time.”

“Off-the-Shelf” Regenerative Medicine

Currently, many regenerative medicine companies suffer significant logistical barriers to scale up and from the proteomic and epigenetic changes induced by DMSO, decreasing therapy efficacy. Cryopreservatives used today are toxic to cells which can lead to cell damage, reduced product yields, and inefficiencies in production. X-Therma’s flagship product XT-Thrive®, a DMSO-, Serum-, Protein-free and chemically defined cryopreservation solution directly plugs into the current CMC workflow, resolves current bottlenecks in the cell manufacturing process, and enables “off-the-shelf” living medicines, and now is receiving hyper-growth customer demand.

“Founded with the mission to enable global organ banking, our platform technology has expanded to all living medicines. Biopreservation is crucial in the evolving regenerative medicine market. It underlies the sourcing of cellular material, manufacture, storage, and delivery of final products,” says Dr. Xiaoxi Wei, CEO & Co-Founder of X-Therma. “Since the onset of the pandemic, the demand for advanced biopharma cold chain solutions has become extremely hot. COVID vaccines have accelerated this growth and exposed cold-chain weaknesses. From day one, our vision has been focused on the heavy lifting of fundamental scientific breakthroughs to solve the soon-to-be bottlenecks still in existence due to a lack of innovation. Our technology supports cell and gene therapy CMC by greatly improving the critical cell preservation process that can make-or-break the delivery of a successful medicine.”

With this new round of funding, the company plans to scale commercialization of XT-Thrive® to meet customer demand for cGMP-grade cell preservation products aimed at Cell and Gene Therapies and tissue engineering users in chemistry, manufacturing, and control processes. Moreover, through its continued partnership with Johns Hopkins University, X-Therma will expand collaboration efforts worldwide and accelerate the regulatory process for organ preservation.

X-Therma will also continue to expand its multi-disciplinary team, filling positions remotely (both nationally and internationally) in its San Francisco Bay Area headquarters and Austria subsidiary. More information on open positions can be found on LinkedIn.

Press Source: Business Wire

About X-Therma

X-Therma is headquartered in Richmond, part of the San Francisco Bay Area, with research centers in Richmond and Berkeley, and now has expanded to Austria in Europe. X-Therma pioneers ground-breaking cold chain technology via a convergent biopreservation platform, to advance Regenerative Medicine and make available safe and on-demand organs, engineered tissues, cell & gene therapies, vaccines, and beyond to patients in need. X-Therma’s technology could be a paradigm shift that makes worldwide organ sharing possible and eliminates organ waiting lists across the globe. X-Therma has been a selected Industrial User at the Lawrence Berkeley National Laboratory and received over $11M contracts and grant support from the U.S. Department of Defense, the National Science Foundation, and the California Institute for Regenerative Medicine. The company recently closed an oversubscribed Series A of $13M.

625 Alfred Nobel Drive
Suite B
Hercules, CA 94547


Kaiserjägerstraße 30
6020 Innsbruck